Pharmaceuticals, Biotechnology and Life Sciences
Mylan is launching Efavirenz Tablets USP, 600 mg, in the USA, the first generic version of Bristol-Myers Squibb’s Sustiva, which…
Mylan and its partner, Aspen have announced the U.S. launch of Myleran (busulfan) Injection, 60 mg/10 mL (6 mg/mL) Single-dose…
Sanofi said Tuesday it filed a patent infringement suit against Mylan in the USA, alleging infringement of 18 patents in its…
Mylan got Monday receipt of tentative approval from the U.S. Food and Drug Administration under the U.S.President’s Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application for Dolutegravir, Lamivudine and Tenofovir Disoproxil Fumarate Tablets.
Mylan N.V. <MYL.O> is best known for producing EpiPen emergency allergy treatments and generic drugs.
The U.S. government may have overpaid drugmaker Mylan N.V. by as much as $1.27 billion between 2006 and 2016 for its EpiPen emergency allergy treatment, the Department of Health and Human Services said on Wednesday.
Mylan has launched of Perphenazine Tablets USP, a generic version of Schering’s Trilafon Tablets 2 mg, 4 mg, 8 mg and 16 mg.
Mylan has acquired the global rights to the Cold-Eeze brand cold remedy line from ProPhase Labs, Inc.
The amount that drugmaker Mylan NV avoided paying the U.S. government in Medicaid rebates for its EpiPen emergency allergy treatment since 2007 likely exceeds a proposed $465 million settlement the company announced in October, according to a study by private drug pricing experts published on Monday.
Mylan has agreed to the terms of a global settlement with Genentech, Inc. and F. Hoffmann-La Roche Ltd. related to patents for Herceptin (trastuzumab), which provides Mylan with global licenses for its trastuzumab product.